Nanomedicine guiding mitochondrial function in the treatment of cardiovascular diseases: Mechanisms, latest developments, and clinical translation
Ageing Research Reviews · 2026-06 · 118 · 103135
DOI: 10.1016/j.arr.2026.103135 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Ageing Research Reviews, 2026-06. Verfasst von Fuyun Jia und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Nanomedicine, Aging, Mitochondria. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Foundation for Support and Development of Education Science and Technology of Mato Grosso do Sul State, Tianjin Municipal Education Commission.
Abstract (Originalsprache)
Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide, and ageing is their strongest biological risk factor. In the ageing cardiovascular system, mitochondrial dysfunction is not only a central driver of disease progression but also a key feature of cardiovascular ageing, linking oxidative stress, calcium dysregulation, bioenergetic failure, impaired mitochondrial dynamics, defective mitophagy, and chronic inflammation to myocardial and vascular decline. In this review, we discuss how age-associated mitochondrial alterations contribute to the pathogenesis of major CVDs and highlight their connections with broader hallmarks of ageing, including cellular senescence, proteostasis disruption, altered intercellular communication, and stem cell exhaustion. We further summarise recent advances in nanomedicine-based strategies targeting and modulating mitochondrial function, including stimulus-responsive nanocarriers, active targeting ligands, biomimetic delivery systems, and combinatorial therapeutic platforms. These approaches show promise in restoring redox balance, improving energy metabolism, limiting apoptosis, and enhancing mitochondrial quality control in conditions such as ischemia-reperfusion injury, hypertension, heart failure, and arrhythmia. Importantly, we also emphasise that ageing itself may substantially influence nanoparticle biodistribution, protein corona formation, immune recognition, intracellular trafficking, and therapeutic efficacy, thereby affecting the translational performance of mitochondrial-targeted nanomedicine in older patients. Although significant progress has been made, challenges remain in biosafety, age-relevant preclinical evaluation, manufacturing scalability, and clinical translation. We further highlight that clinical translation remains constrained by limited cardiovascular clinical evidence, patient heterogeneity, and age- and comorbidity-dependent variability in nanoparticle safety and efficacy. Overall, framing mitochondrial-targeted nanomedicine within the biology of cardiovascular ageing may provide a more precise and clinically relevant strategy for preventing and treating age-related CVDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China.
- Department of Cardiovascular, Xingyi People's Hospital, Guizhou 562400, China.
- Graduate School of Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
- The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China. Electronic address: tcmxuqiang@hotmail.com.
Förderung
- Foundation for Support and Development of Education Science and Technology of Mato Grosso do Sul State
- Tianjin Municipal Education Commission
Zitieren
APA
Jia, F., Xia, X., Song, Y., Chen, Y., Pang, J., Zhang, X., & Xu, Q. (2026). Nanomedicine guiding mitochondrial function in the treatment of cardiovascular diseases: Mechanisms, latest developments, and clinical translation. Ageing Research Reviews, 118, 103135. https://doi.org/10.1016/j.arr.2026.103135
Vancouver
Jia F, Xia X, Song Y, Chen Y, Pang J, Zhang X, et al. Nanomedicine guiding mitochondrial function in the treatment of cardiovascular diseases: Mechanisms, latest developments, and clinical translation. Ageing Research Reviews. 2026;118:103135. doi:10.1016/j.arr.2026.103135
BibTeX
@article{Jia2026,
author = {Jia, Fuyun and Xia, Xiangchen and Song, Yuchen and Chen, Yicheng and Pang, Jianzhong and Zhang, Xi and Xu, Qiang},
title = {Nanomedicine guiding mitochondrial function in the treatment of cardiovascular diseases: Mechanisms, latest developments, and clinical translation},
journal = {Ageing Research Reviews},
year = {2026},
volume = {118},
pages = {103135},
doi = {10.1016/j.arr.2026.103135}
}
EUVIMED